Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
Authors:
- Mary E.R. O’brienMary E.R. O’brien
- Rabab GaafarRabab Gaafar
- Baktiar HasanBaktiar Hasan
- Jessica MenisJessica Menis
- Tanja CuferTanja Cufer
- Sanjay PopatSanjay Popat
- Penella J. WollPenella J. Woll
- Veerle SurmontVeerle Surmont
- Vassilis GeorgouliasVassilis Georgoulias
- Ana MontesAna Montes
- Fiona BlackhallFiona Blackhall
- Ivo HennigIvo Hennig
Open Access
- 1 August 2015
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (12) , 1511-1528
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient dataThe Lancet Oncology, 2014
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialThe Lancet, 2014
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trialThe Lancet Oncology, 2012
- Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyThe Lancet, 2009
- A Comparison of Phase II Study StrategiesClinical Cancer Research, 2009
- Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2009
- Interim futility analysis with intermediate endpointsClinical Trials, 2008
- Analysis of progression‐free survival in oncology trials: some common statistical issuesPharmaceutical Statistics, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006